Suptavumab
Suptavumab (INN;[1] development code (REGN2222) is a humanized monoclonal antibody designed for the prevention of medically attended lower respiratory tract disease due to respiratory syncytial virus.
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | respiratory syncytial virus fusion protein |
| Clinical data | |
| Other names | REGN2222 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6502H10038N1726O2020S42 |
| Molar mass | 146054.41 g·mol−1 |
This experimental drug candidate was being developed by Regeneron Pharmaceuticals Inc until it was discontinued after unsuccessful Phase III clinical trials.[2][3]
References
- World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
- Statement On A Nonproprietary Name Adopted By The USAN Council - Suptavumab, American Medical Association.
- "Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus" (Press release). Regeneron. August 14, 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.